Heterobicyclic spiro compounds or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing these compounds, and in the preparation of drugs for treating mammalian Alzheimer's disease and insulin resistance syndrome and type 2 diabetes Use of compounds
There are disclosed bicyclic heterocyclic spiro compounds; pharmaceutical compositions comprising these compounds; and methods for the treatment in a mammal of diseases and conditions which are susceptible to modulation of the M1 muscarinic receptor, including Alzheimer's disease, insulin resistance syndrome and type 2 diabetes. Other embodiments are also disclosed.